Dublin, Aug. 25, 2017 -- The "United States Insulin Pump Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022" report has been added to Research and Markets' offering.
This is the 2nd latest edition report published by the Market Report Publisher. United States Insulin Pump Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022 provides a deep and thorough evaluation of the United States Insulin Pump Market. The report provides an in-depth analysis of the type 1, type 2 and newly diagnosed type 1 diabetes and overall diabetes population.
Market growth can be attributed to factors such as increasing number of diabetic patients, growing awareness towards diabetes, improved glucose control and flexible, lifestyle-compatible treatment options and technological advancement in insulin pump devices. However, high cost of the insulin pump devices is expected to hamper growth of the market during forecast period.
It provides essential insights into insulin pump users with more focused on type 1 and type 2 diabetes insulin pump users. Market outlook in value terms has been analysed based on current and potential trends and the market is estimated from 2017 to 2022. Additionally, the report includes assessment of clinical trials and preferred insulin pump brand by the patients. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the United States Insulin Pump Market.
The report concludes with the profiles of major players in the Insulin Pump Market such as Insulet Corporation, Medtronic, Roche, Animas Corporation and Tandem Diabetes Care. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of the Insulin Pump and Diabetes Market from 2011 to 2022.
Key Topics Covered in the Report:
- United States Diabetes Population (2011 - 2022)
- United States Insulin Pump Users and Market Analysis (2011 - 2022)
- United States Insulin Pump Preferred Brand - By Product
- United States Insulin Pump Market: Reimbursement & Regulation System
- United States Insulin Pump Market - Major Deal Types
- Insulin Pump Market Clinical Trail Insight by Phase, Company & Country
- Key Companies Analysis
- Key Drivers and Inhibitors of the United States Insulin Pump Market
Key Companies Covered in the Report are as follows:
- Insulet Corporation
- Medtronic
- Roche
- Animas Corporation and
- Tandem Diabetes Care
Key Topics Covered:
1. Executive Summary
2. United States Diabetes Population (2011 - 2022): An Analysis
2.1 Overall Diabetes Population
2.1.1 Type 1 Diabetes
2.1.2 Type 2 Diabetes
2.1.3 Newly Diagnosed Type 1 Diabetes
3. United States Insulin Pump Market Analysis (2011- 2022)
3.1 Insulin Pump Users
3.1.1 Type 1 Diabetes Insulin Pump Users
3.1.2 Type 2 Diabetes Insulin Pump Users
3.2 Insulin Pump Market
4. Key Drivers and Inhibitors of the United States Insulin Pump Market
4.1 Market Drivers
4.2 Inhibitors
5. United States Insulin Pump Preferred Brand - By Product
5.1 Pediatric
5.2 Adult
6. United States Insulin Pump Market: Reimbursement & Regulation System
6.1 Reimbursement System
6.2 Regulation System
7. United States Insulin Pump Market - Major Deal Types
7.1 Insulin Pump Market - Collaboration Deals
7.2 Insulin Pump Market - Licensing Agreement
7.3 Insulin Pump Market - Exclusive Agreement
7.4 Insulin Pump Market - Partnerships Deals
8. Insulin Pump Market Clinical Trail Insight by Phase, Company & Country
8.1 Year 2016
8.2 Year 2015
8.3 Year 2014
8.4 Year 2013
8.5 Year 2012
9. Key Companies Analysis
- Animas Corporation
- Insulet Corporation
- Medtronic
- Roche
- Tandem Diabetes Care
For more information about this report visit https://www.researchandmarkets.com/research/jzlff3/united_states
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices , Infusions and Injectables


Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Instagram Outage Disrupts Thousands of U.S. Users 



